Beam Therapeutics Inc. (BEAM) News

Beam Therapeutics Inc. (BEAM): $46.82

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BEAM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter BEAM News Items

BEAM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BEAM News Highlights

  • For BEAM, its 30 day story count is now at 11.
  • Over the past 10 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • GENE, BASE and AMGN are the most mentioned tickers in articles about BEAM.

Latest BEAM News From Around the Web

Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

In this article, we discuss the top 15 companies in Alphabet Inc (GOOGL)’s investment portfolio. If you want to see more names in this portfolio, check out Alphabet Inc (GOOGL) Investment Portfolio: Top 5 Companies. GV, previously named Google Ventures, is the venture capital investment arm of Alphabet Inc. (NASDAQ:GOOG), which was founded in 2009 […]

Yahoo | November 17, 2022

10 Most Promising Gene Therapy Companies to Watch

In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […]

Yahoo | November 14, 2022

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United StatesCAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in adult

Yahoo | November 14, 2022

Beam Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: 2022 Jefferies London Healthcare Conference (fireside chat) on Tuesday, November 15, 2022, at 8:00 a.m. GMT; and,Evercore ISI Virtual HealthCONx Conference 2022 (fireside chat) on Thursday, December 1, 2022, at 8:50 a.m. ET. Li

Yahoo | November 9, 2022

Beam Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Beam Therapeutics ( NASDAQ:BEAM ) Third Quarter 2022 Results Key Financial Results Revenue: US$15.8m (up by US$15.0m...

Yahoo | November 9, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Xencor (XNCR) and Beam Therapeutics (BEAM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Xencor (XNCR – Research Report) and Beam Therapeutics (BEAM – Research Report). Amgen (AMGN) BMO Capital analyst Evan Seigerman maintained a Hold rating on Amgen today and set a price target of $260.00. The company's shares closed last Tuesday at $289.95. According to TipRanks.

Brian Anderson on TipRanks | November 8, 2022

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Cardinal Health (CAH) and Beam Therapeutics (BEAM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN – Research Report), Cardinal Health (CAH – Research Report) and Beam Therapeutics (BEAM – Research Report). Illumina (ILMN) Morgan Stanley analyst Tejas Savant maintained a Hold rating on Illumina today and set a price target of $225.00. The company's shares closed last Monday at $215.91. According to TipRanks.

Brian Anderson on TipRanks | November 7, 2022

Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy

Last November, the FDA signed off Beam Therapeutics Inc's (NASDAQ: BEAM) Investigational New Drug (IND) application for Phase 1/2 trial for BEAM-101 gene therapy for sickle cell disease. In the most recent earnings release, the company said it is still working on enrolling its first patient for the trial, dubbed BEACON-101, by year-end. The company announced in its Q3 update that it's pushing back plans to file an IND in 2022 for BEAM-102, another sickle cell gene therapy candidate. To speed up

Yahoo | November 7, 2022

Why Beam Therapeutics Stock Is Falling Today

Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.

Yahoo | November 7, 2022

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6486 seconds.